Dexamethasone phosphate 4 mg/ml solution for injection/infusion

DRUG3 trials

Sponsors

Regeneron Pharmaceuticals Inc.

Conditions

High-Risk Monoclonal Gammopathy of Undetermined Significance; Non-High-Risk Smoldering Multiple MyelomaRelapsed or Refractory Multiple MyelomaRelapsed or Refractory Systemic Light Chain Amyloidosis

Phase 1

A Phase 1/2 Study of Linvoseltamab in Patients with Relapsed or Refractory Systemic Light Chain Amyloidosis

RecruitingCTIS2023-507809-34-00

Regeneron Pharmaceuticals Inc.Relapsed or Refractory Systemic Light Chain Amyloidosis

Start: 2024-08-07Target: 27Updated: 2025-09-24

PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

RecruitingCTIS2024-511454-45-00

Regeneron Pharmaceuticals Inc.Relapsed or Refractory Multiple Myeloma

Start: 2020-11-09Target: 16Updated: 2025-11-21

Phase 2

PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA

RecruitingCTIS2023-505242-25-00

Regeneron Pharmaceuticals Inc.High-Risk Monoclonal Gammopathy of Undetermined Significance; Non-High-Risk Smoldering Multiple Myeloma

Start: 2024-11-05Target: 86Updated: 2026-01-05